Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Summary

The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.

Timeline

Start

2011-06

Primary completion

2013-10

Completion

2015-03

Drugs

Indications